See every side of every news story
Published loading...Updated

PTC Therapeutics (NASDAQ:PTCT) Trading Down 8.8% Following Analyst Downgrade

Summary by americanbankingnews.com
PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report)’s share price traded down 8.8% during trading on Monday after JPMorgan Chase & Co. lowered their price target on the stock from $78.00 to $75.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. PTC Therapeutics traded as low as $45.40 and last traded […]
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

americanbankingnews.com broke the news in on Wednesday, April 2, 2025.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.